Healthcare Industry News: Shlomo Yanai
News Release - March 7, 2007
Teva Announces the Office of the Chief Executive OfficerGeorge Barrett appointed EVP, Global Pharmaceutical Markets
Amir Elstein appointed EVP, Global Resources
JERUSALEM--(HSMN NewsFeed)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA ) today announced the Office of the Chief Executive Officer, which will now include George Barrett, President & CEO, Teva North America; and Amir Elstein, Vice President, Global Specialty Pharmaceutical Products. Mr. Barrett will assume the additional role of Executive Vice President, Global Pharmaceutical Markets, and Mr. Elstein will assume the additional role of Executive Vice President, Global Resources. The goal of the office is to more effectively align the Company's operations with its corporate strategy to solidify Teva's market leadership in a rapidly evolving global healthcare industry.
Mr. Barrett's expanded global role will include identifying potential new markets and segments that will extend Teva's leadership and maintain its competitive advantage, ensuring consistency in strategy and execution across all global markets and therapeutic groups, overseeing merger integrations and extracting synergies across all business lines to optimize the portfolio, and continuing to represent the Company with key external audiences.
Mr. Elstein's expanded role will include ensuring reliable operating capacity for Teva's entire product line; ensuring the development and launch teams work optimally in serving the needs of new products across all territories; assisting in the preparation of strategic work-plans in the global resources groups; and overseeing the development and operation of the supply, technology and information systems.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80% of Teva's sales are in North America and Europe.
Source: Teva Pharmaceutical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.